Abstract ISI
JOURNAL OF CLINICAL ONCOLOGY  (2013)

A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for HER2 overexpressing metastatic breast cancer (MBC).

Papadimitriou, CA; Sarosiek, T; Pikiel, J; Karaszewska B.; Salat C.; Caglevic C.; Potemski, P; Brain, E; Briggs, KJ; DeSilvio, M; Marini, L; Janni, W